| Date | Title | Description |
| 17.10.2024 | Tecnopolo Ticino celebrates a decade of helping innovative companies scale up |
In 2024, Tecnopolo Ticino celebrates its 10th anniversary, marking a decade of fostering innovation and entrepreneurship in Canton Ticino. Over the past ten years, it has played a key role in the development of 72 companies, which have col... |
| 02.10.2024 | ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City | Conference to Feature Leading Healthcare Companies and Institutional Investors for 1x1/Small Group Meetings and Panels
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to a... |
| 14.06.2024 | Gain Therapeutics Announces Pricing of $11.0 Million Public Offering | BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offerin... |
| 13.06.2024 | Gain Therapeutics Announces Pricing of $11.0 Million Public Offering | BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offerin... |
| 05.03.2024 | Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease | - |
| 03.05.2023 | Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease | - |
| 28.04.2023 | Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million | |
| 02.03.2022 | Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022 | “AI will continue to have a demonstrable impact on human health. Having spent the last three years ideating with my fellow charter members to establish AAIH, I’m honored to take the reins and thrilled I get to engage with an incredible team... |
| 08.02.2022 | Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022 | BETHESDA, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators (STARs) identified with its ... |
| 18.01.2022 | Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences | - Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable -
- 18th Annual WORLDSymposium –
- AD/PD™ 2022 -
BETHESDA, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasd... |
| 29.12.2021 | Gain Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Form 8-K | Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BETHESDA, MD, December 28, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a biotechnology comp... |
| 29.12.2021 | Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BETHESDA, Md., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegener... |
| 12.11.2021 | Gain Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Business Update - Form 8-K | Gain Therapeutics, Inc.
Reports Third Quarter 2021 Financial Results and Business Update
Data from Patient-Derived iPSC Study Evaluating STAR Compounds Show Positive Effects on Disease Onset and Progression; Full Data Presented at MJFF's Pa... |
| 12.11.2021 | Gain Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Business Update | Data from Patient-Derived iPSC Study Evaluating STAR Compounds Show Positive Effects on Disease Onset and Progression; Full Data Presented at MJFF’s Parkinson's Disease Therapeutics Conference
---
Appoints
Matthias Alder as Chief Operating ... |
| 04.11.2021 | Gain Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference | In-Person Dates: November 16th-17th
Virtual Dates: November 18th-19th
BETHESDA, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and opt... |
| 26.10.2021 | Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB) | BETHESDA, Md., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegener... |
| 20.10.2021 | Gain Therapeutics : Appoints Matthias Alder as Chief Operating Officer - Form 8-K | Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer
BETHESDA, MD, October 19, 2021 - Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a biotechnology company focused on identifying and ... |
| 08.09.2021 | Press Release : Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson's Disease | GT-02287and GT-02329 compounds display positive effects on GCase activity
and related parameters
---
Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and decrease of glucosylceramide and -synucle... |
| 08.09.2021 | Gain Therapeutics : Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson's Disease | GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters
---
Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and decrease of glucosylceramide and α-synucl... |
| 02.09.2021 | Gain Therapeutics : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference | BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegene... |
| 27.05.2021 | GAIN THERAPEUTICS, INC.
Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference | BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been... |
| 17.05.2021 | GAIN THERAPEUTICS, INC.
Gain Therapeutics : to Participate in Upcoming Virtual Investor Conferences in May | BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been... |
| 27.04.2021 | GAIN THERAPEUTICS, INC.
Gain Therapeutics to Present at the B. Riley Securities' Virtual Neuroscience Conference | BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before bee... |
| 19.03.2021 | Gain Therapeutics raised $46 million through Nasdaq listing | |
| 19.03.2021 | Gain Therapeutics raised $46 million through Nasdaq listing | Gain Therapeutics offers 3,636,364 shares of its common stock at a price of $11.00 per share. The shares began trading on the Nasdaq Global Market on March 18, 2021 under the symbol “GANX.” On the first trading day the shares closed at $11.... |
| 22.07.2020 | Gain Therapeutics secures $10 million | Gain Therapeutics is a biotechnology company focused on developing first-in-class medicines that target novel allosteric binding sites on enzymes for the treatment of rare genetic and CNS diseases. Gain’s patented and proprietary computatio... |
| 22.07.2020 | Gain Therapeutics secures $10 million | |
| 21.07.2020 | Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing | Eric I Richman appointed CEO and Director |
| 21.07.2020 | Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing | Financing intended to accelerate IND-enabling studies of allosteric drug candidates for rare
genetic and neurodegenerative diseases, expand pipeline and support business development
activities
Eric I Richman appointed CEO and Director
BETHE... |
| 26.07.2019 | EUR 1.4m grant for Gain Therapeutics | |
| 01.04.2019 | Swiss Biotech Day to shed light on 13 emerging startups | |
| 13.03.2019 | Two foundations join forces to fund Gain Therapeutics’ approach for Parkinson’s | |
| 20.02.2019 | Ticino-based Gain Therapeutics raises €2.5 million in Series A | |
| 19.02.2019 | Gain Therapeutics Closes €2.5M Series A Financing | GT Gain Therapeutics SA, a Lugano, Switzerland-based preclinical stage biotech company, closed a €2.5M Series A financing.
Backers included:
– VitaTech S.A. (€1.1Mio),
– Helsinn Investment Fund S.A. (€1Mio), and
– TiVenture S.A. (€0.4).
The... |
| 19.02.2019 | Helsinn Investment Fund Invests €1 Million in Gain Therapeutics | Luxembourg, 19 February 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces that it has made a €1 Million investment in Gain Therapeutics SA... |
| 20.02.2018 | Gain Therapeutics spins off to develop treatments for rare metabolic disorders | |
